SPC
NTLA icon

Sigma Planning Corp’s Intellia Therapeutics NTLA Stock Holding History

Sigma Planning Corp’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,616
Closed -$99.6K – 1350
2025
Q2 		$99.6K Buy
+10,616
New +$87.2K ﹤0.01% 1208

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sigma Planning Corp's NTLA Position: Q3 2025 in Review

Sigma Planning Corp sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 10,616 shares — an estimated $99.6K sold.

Sigma Planning Corp first reported a position in NTLA in Q2 2025 and held it in 1 quarter. The position peaked at $99.6K in Q2 2025. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Sigma Planning Corp reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sigma Planning Corp sold 10,616 Intellia Therapeutics shares in Q3 2025, an estimated $99.6K.
  • Sigma Planning Corp first reported a position in Intellia Therapeutics in Q2 2025 and held it in 1 quarter.
  • Sigma Planning Corp's Intellia Therapeutics position peaked at $99.6K in Q2 2025.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Sigma Planning Corp's 13F filing for Q3 2025, filed 10 Nov 2025.